In this study, we established a noninvasive risk model using a blood IRPS (TMB, TP53, KRAS, EGFR and SMAD4) in Qujing patients with advanced NSCLC to better compensate for the shortfalls of existing prognostic signatures. Here, KRAS is linked to non-small cell lung carcinoma.